ARTICLE | Clinical News
Viekira XR ombitasvir/paritaprevir/ritonavir/dasabuvir regulatory update
August 8, 2016 7:00 AM UTC
FDA approved an NDA from AbbVie for Viekira XR ombitasvir/paritaprevir/ritonavir/dasabuvir to treat chronic HCV genotype 1 infection, including patients with compensated cirrhosis. Viekira XR is indic...